Literature DB >> 17338626

Effect of dietary control of urinary uric acid excretion in calcium oxalate stone formers and non-stone-forming controls.

Vernon M Pais1, Ross P Holmes, Dean G Assimos.   

Abstract

BACKGROUND AND
PURPOSE: Hyperuricosuria is a well-recognized risk factor for calcium oxalate urolithiasis. Some studies have demonstrated elevated urinary uric acid excretion in stone formers compared with non-stone-forming controls; nevertheless, these studies were limited by patient consumption of self-selected diets. With the recognition that dietary differences may induce variations in urinary uric acid excretion, we evaluated excretion of this compound in stone formers and controls consuming a standardized diet. SUBJECTS AND METHODS: A standardized formula diet was administered to 65 calcium oxalate stone formers and 61 age-matched non-stone-forming controls. During the 3 days of dietary intervention, 24-hour urine collections were obtained. Mean urinary uric acid excretion indexed to urinary creatinine was calculated for each subject, and the results in the two groups were compared.
RESULTS: Stone-forming subjects did not have an elevation in urinary uric excretion compared with control subjects, with mean indexed urinary uric acid excretions of 337 +/- 64 mg/g of creatinine and 379 +/- 76 mg/g of creatinine, respectively.
CONCLUSIONS: With dietary standardization, there was no observed increase in urinary uric acid excretion in our sampled populations. These findings emphasize the role of dietary factors in urinary uric acid excretion and highlight the potential value of dietary interventions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17338626      PMCID: PMC2705619          DOI: 10.1089/end.2007.2218

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  17 in total

1.  Sodium urate accelerates precipitation of calcium oxalate in vitro.

Authors:  F L Coe; R L Lawton; R B Goldstein; V Tembe
Journal:  Proc Soc Exp Biol Med       Date:  1975-09

2.  Allopurinol treatment of uric-acid disorders in calcium-stone formers.

Authors:  F L Coe; L Raisen
Journal:  Lancet       Date:  1973-01-20       Impact factor: 79.321

3.  Uricemia and urolithiasis.

Authors:  M J Smith; L D Hunt; J S King; W H Boyce
Journal:  J Urol       Date:  1969-05       Impact factor: 7.450

Review 4.  Molecular physiology of urate transport.

Authors:  Matthias A Hediger; Richard J Johnson; Hiroki Miyazaki; Hitoshi Endou
Journal:  Physiology (Bethesda)       Date:  2005-04

5.  Hyperuricosuric calcium oxalate nephrolithiasis.

Authors:  F L Coe
Journal:  Kidney Int       Date:  1978-05       Impact factor: 10.612

6.  Risk factors in calcium stone disease of the urinary tract.

Authors:  W G Robertson; M Peacock; P J Heyburn; D H Marshall; P B Clark
Journal:  Br J Urol       Date:  1978-12

7.  Uric acid disorders in patients with calcium stones.

Authors:  A Hodgkinson
Journal:  Br J Urol       Date:  1976-02

8.  Twenty-four-hour urine chemistries and the risk of kidney stones among women and men.

Authors:  G C Curhan; W C Willett; F E Speizer; M J Stampfer
Journal:  Kidney Int       Date:  2001-06       Impact factor: 10.612

9.  Urinary excretion of urate in renal calcium stone disease and in renal tubular acidification disturbances.

Authors:  B Fellström; U Backman; B G Danielson; G Johansson; S Ljunghall; B Wikström
Journal:  J Urol       Date:  1982-03       Impact factor: 7.450

10.  Idiopathic calcium nephrolithiasis. 1. Differences in urine crystalloids, urine saturation with brushite and urine inhibitors of calcification between persons with and persons without recurrent kidney stone formation.

Authors:  G Pylypchuk; U Ehrig; D R Wilson
Journal:  Can Med Assoc J       Date:  1979-03-17       Impact factor: 8.262

View more
  1 in total

1.  SLC2A9 Genotype Is Associated with SLC2A9 Gene Expression and Urinary Uric Acid Concentration.

Authors:  Erin B Ware; Ellen Riehle; Jennifer A Smith; Wei Zhao; Stephen T Turner; Sharon L R Kardia; John C Lieske
Journal:  PLoS One       Date:  2015-07-13       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.